Dr. Sehn Discusses the GAUSS Obinutuzumab Trial

Video

Dr. Laurie Sehn, from the British Columbia Cancer Agency, Discusses the GAUSS Obinutuzumab Trial

Laurie H. Sehn, MD, MPH, clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, discusses the phase II randomized GAUSS trial that demonstrated a trend towards a higher objective response rate to obinutuzumab (GA101) compared with rituximab (Rituxan), for patients with indolent non-Hodgkin lymphoma.

Sehn describes the GAUSS trial as the first head-to-head comparison of a novel CD20 monoclonal antibody and rituximab.

Patients in the trial were randomized 1:1 to receive either obinutuzumab or rituximab in 4 weekly induction therapies. Response was assessed following the induction treatment at 24 and 48 days. Patients that did not demonstrate any evidence of disease progression received a maintenance therapy of obinutuzumab or rituximab every 2 months for 2 years.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD